Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter Open Label Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) in Patients Newly Diagnosed.

NCT04138875 is registered in ClinicalTrials.gov with Yale University as lead sponsor.

NCT NCT04138875
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04138875 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter Open Label Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB) in Patients Newly Diagnosed.
Lead sponsor
Yale University
Phase
Phase 2
Overall status
Withdrawn
Start date
January 31, 2022
Completion date
December 31, 2023
Enrollment
0 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

classical hodgkin lymphoma type ptld, florid follicular hyperplasia ptld, hematopoietic/lymphoid cancer, infectious mononucleosis, lymphoid tumor, monomorphic ptld, plasmacytic hyperplasia ptld, polymorphic ptld, ptld